Please assess the completion status of the following clinical trial:

Trial Title: A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~MAIN PART:~1. Healthy Japanese male and female adult participants aged \>= 20 years of age at the time of signing of informed consent.~2. Participant who completed 2 doses primary vaccinations with another specified mRNA vaccine which is available in Japan 6 to 12 months prior to the trial vaccination.~   EXTENSION PART:~3. Participants who received the first trial vaccination at least 5 months earlier and are currently enrolled in the Main Part (ie, not have withdrawn or discontinued early).~Exclusion Criteria:~MAIN PART:~1. Participants who received any other SARS-CoV-2 vaccine (except for the specified mRNA vaccine) or other experimental novel coronavirus vaccine prior to the trial.~2. Participant who received a booster vaccination (i.e. 3rd dose)~3. Participants who have close contact of anyone known to have COVID-19 within 14 days prior to the trial vaccination.~4. Participants who were tested positive for SARS-CoV-2 prior to the trial.~5. Participants who have traveled outside of Japan in the 30 days prior to the trial participation.~6. Participants with a clinically significant active infection or oral temperature \>= 38 degree Celsius within 3 days of the intended date of the first single booster vaccination.~7. Participants with body mass index (BMI) greater than or equal to 30 kg/m\^2 (BMI= weight in kg/ height in meters\^2)~   EXTENSION PART:~8. Participants with a clinically significant active infection or oral temperature \>=38 degree Celsius within 3 days of the intended date of the second single booster vaccination.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- TAK-019 Main Part (Type: EXPERIMENTAL): TAK-019 0.5 mL, intramuscular injection in the mid deltoid, preferable in the non-dominant upper arm
- TAK-019 Extension Part (Type: EXPERIMENTAL): TAK-019 0 .5 mL, intramuscular injection in the mid deltoid, preferable in the non-dominant upper arm. The participants who received the first single booster vaccination of TAK-019 in the main part and remained in study follow-up at least 5 months will receive a second single booster vaccination of TAK-019 by intramuscular injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).